Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

Phase 1GB10 InjectionPositive

AI Analysis

Summary

Shenzhen Kexing Pharmaceutical has enrolled the first subject in a Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug. The company aims to advance this independently developed therapeutic candidate through initial human testing.

Clinical Trial Data

Phase

Phase I

Outcome Details

First subject enrolled and dosed

Importance:3/10

Sentiment:

0.30

Phase 1ophthalmicChinaclinical trial initiation

Related Companies

$CPHI $TRAX

Read the original article

Published by PR Newswire Biotech on June 4, 2026 10:53 AM

Read Original